摘要
目的探讨行前哨淋巴结活检的保乳术联合白蛋白结合型紫杉醇治疗乳腺癌效果及对人宫颈癌基因(HCCR)-1影响。方法以开展行前哨淋巴结活检的保乳术联合白蛋白结合型紫杉醇治疗时间为截点,选取2018年11月—2020年11月收治的乳腺癌55例作为对照组(行前哨淋巴结活检的保乳术治疗),2020年12月—2021年12月收治的乳腺癌55例作为观察组(行前哨淋巴结活检的保乳术联合白蛋白结合型紫杉醇治疗)。比较2组入院时及治疗后2、3个月HCCR-1阳性检出率,入院时及治疗后2个月T淋巴细胞水平,治疗后6个月的临床效果,以及观察组治疗期间毒副作用。结果治疗后2和3个月,乳腺癌病灶和周围组织HCCR-1阳性检出率2组均低于入院时,观察组均低于对照组(P<0.05)。治疗后2个月,CD3+、CD4+和CD4+/CD8+2组均较治疗前升高,且观察组高于对照组(P<0.05)。治疗后6个月,观察组完全缓解率74.55%(41/55)高于对照组52.73%(29/55)(P<0.05)。治疗期间,观察组出现恶心呕吐11例,皮肤潮红2例,骨髓抑制1例,给予对症治疗均在2周内恢复正常。结论行前哨淋巴结活检的保乳术联合白蛋白结合型紫杉醇治疗乳腺癌可降低HCCR-1水平,促进免疫指标恢复,改善近期疗效,且毒副作用较小。
Objective To investigate the effect of breast-conserving surgery plus sentinel lymph node biopsy combined with Nab-paclitaxel in the treatment of breast cancer and their impact on human cervical cancer gene-1(HCCR-1).Methods With the cut-off time of breast-conserving surgery plus sentinel lymph node biopsy combined with Nab-paclitaxel treatment,55 patients with breast cancer admitted from November 2018 to November 2020 were selected as the control group(receiving breast-conserving surgery plus sentinel lymph node biopsy).Another 55 patients with breast cancer admitted from December 2020 to December 2021 were included as the observation group(breast-conserving surgery plus sentinel lymph node biopsy combined with Nab-paclitaxel treatment).The positive detection rate of HCCR-1 at admission and at 2 and 3 months after treatment,the level of T lymphocytes at admission and at 2 months after treatment,the clinical effect at 6 months after treatment in the two groups as well as the toxic and side effects during treatment in the observation group,were compared.Results At 2 and 3 months after treatment,the positive detection rate of HCCR-1 in breast cancer lesions and surrounding tissues in the two groups was lower than that at admission,and lower in the observation group than in the control group(P<0.05).At 2 months after treatment,CD3+,CD4+and CD4+/CD8+in the two groups were higher than those before treatment,and higher in the observation group than in the control group(P<0.05).At 6 months after treatment,the complete remission rate of observation group was 74.55%(41/55),which was higher than that of control group[52.73%(29/55)](P<0.05).In the observation group,nausea and vomiting occurred in 11 patients,skin flushing in 2 patients(3.64%),and myelosuppression in 1 patient(1.82%)during treatment.After symptomatic treatment,all patients recovered to normal within 2 weeks.Conclusion Breast conserving surgery plus sentinel lymph node biopsy combined with Nab-paclitaxel in the treatment of breast cancer can reduce the expression level of HCCR-1,promote the recovery of immune indicators,and improve the short-term efficacy,with fewer toxic and side effects.
作者
赵广章
刘海英
张开通
李磊
熊斌
ZHAO Guangzhang;LIU Haiying;ZHANG Kaitong;LI Lei;XIONG Bin(Department of Breast Surgery,the Affiliated Hospital of Jining Medical College,Jining,Shandong 272007,China;Department of Oncology,the Affiliated Hospital of Jining Medical College,Jining,Shandong 272007,China;Department of Pathology,the Affiliated Hospital of Jining Medical College,Jining,Shandong 272007,China;Breast Disease Center,Beijing Tongren Hospital Affiliated to Capital Medical University,Beijing 100005,China)
出处
《转化医学杂志》
2023年第3期167-172,共6页
Translational Medicine Journal
基金
山东省医药卫生科技发展计划项目面上项目(202104010714)。
